Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia

Leukemia

Volumn 9, Issue 6, 1995, Pages 1104-1107

  Rozman, C ^a   Urbano Ispizua, A ^a   Cervantes, F ^a   Rozman, M ^a   Colomer, D ^a   Feliz P ^a   Pujades, A ^a   Vives Corrons, J L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CML; Molecular analysis; Prognosis; Thrombopoiesis

Indexed keywords

BCR ABL PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CHIMERA; CHROMOSOME 22; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; HUMAN CELL; MALE; MEGAKARYOCYTE; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RNA ANALYSIS; SOUTHERN BLOTTING;

EID: 0029071590     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schaefer-Rego K et al. CML patients in blast crisis have breakpoints localised to a specific region of the BCR. Blood 1987; 70: 448-455.
2. Mills KI et al. Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic factor. Leukemia 1989, 3: 837-840.
3. Inokuchi K et al. The relationship between the site of breakpoints within the BCR gene and thrombopoiesis of Philadelphia-positive chronic myelocytic leukemia. Leuk Res 1991; 15: 1067-1073.
4. Mills KI, McKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72: 1237-1241.
5. Eisenberg A, Silver R, Soper L. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 1988; 2: 642-647.
6. Inokuchi K et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78: 3125-3127.
7. Lee M et al. Clinical investigation of bcr/abl splicing patterns by polymerase chain reaction (PCR) in Philadelphia chromosome (Ph') positive chronic myelogenous leukemia (CML). Blood 1990; 76: 294a (abstr.).
8. Arden JC et al. Molecular analysis in chronic granulocytic leukemia: location of breakpoints within M-BCR and relationship with presentation platelet counts. Clin Lab Haematol 1993; 15: 253-258.
9. Mills KL, Sproul AM, Leibowitz D, Burnett AK. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukemia patients with a breakpoint around exon 14 (b3) of the BCR gene. Leukemia 1991; 5: 937-941.
10. Shtalrid M et al. Analysis of breakpoints within the bcr gene and their correlations with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988; 72: 485-490.
11. Przepiorka D. Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genet Cytogenet 1988; 36: 117-122.
12. Jaubert J et al The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia. Br J Haematol 1990; 74: 30-35.
13. Morris SW et al. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035-2041.
14. Tien HF et al. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical status and prognosis of the disease. Br J Haematol 1990; 75: 469-475.
15. Zaccaria A et al M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 1992; 77: 16-20.
16. Opalka B et al. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood 1992; 80: 1854-1858.
17. Shepherd P, Bond C, Allan NC. Molecular breakpoints and platelet counts in chronic myeloid leukemia. Blood 1992; 80: 556-563 (letter).
18. Sokal JE et al, and The Italian Cooperative CML Study Croup. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
19. Maniatis TE, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1982.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
21. Cervantes F, Rozman C, Feliu E. Prognostic evaluation of initial bone marrow histopathological features in chronic granulocytic leukemia. Acta Haematol 1989; 82: 12-15.
22. Dixon WJ et al. BMDP statistical software. University California Press: Berkeley, 1988.
23. Shtivelman E, Gale RP, Dreazen O. bcr-abl RNA in patients with chronic myelogenous leukemia. Blood 1987; 69: 971-973.
24. Fioretos T et al. Clinical impact of breakpoint position within Mbcr in chronic myeloid leukemia. Leukemia 1993; 7: 1225-1231.
25. Ogawa H et al. No correlation between locations of breakpoints and clinical status in Ph'-positive CML patients. Leukemia 1989; 3: 492-496.
26. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-BCR) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991; 78: 1155-1161.
27. Nakamura K et al. Molecular studies of chronic myelogenous leukemia using the polymerase chain reaction. Cancer 1991; 68: 2426-2430.
28. Zaccaria A et al. The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. Br J Haematol 1993; 84: 265-268.
29. Inokuchi K, Nomura T. The relationship between the type of bcr/abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia. Leuk Lymphoma 1993; 10: 9-15.
30. Tanabe Y et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood 1991; 78: 3125-3126.